| abstract |
A method of selecting a therapeutic agent for retinal denaturation or retinal denaturation-associated disease for a patient with retinal denaturation or retinal denaturation-associated disease, comprising (i) a step to examining the genotypes of the HLA-A gene locus, the HLA-B gene locus, and the HLA-DR gene locus of patient-derived T cells, (ii) a step to select a retinal pigment epithelial cell having a allele matching the allele at each gene locus clarified in stage (i), in which the retinal pigment epithelial cell in stage (ii) has an HLA-A gene locus, an HLA-gene locus B and one HLA-DR gene locus, and one genotype of each locus is homozygous. |